Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Neoadjuvant to Adjuvant Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer
NCT06348134Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Mar 2025
- Primary completion
- Jul 2034
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab, trastuzumab, trastuzumab emtansine in breast cancer, sponsored by University of Chicago. Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06348134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06348134.